Recurrent small cell lung cancer: Update

Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer

1985 • 1,360 citations

A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.

2001 • 988 citations

Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

2000 • 934 citations

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

1999 • 909 citations

Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.

2000 • 766 citations

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

1997 • 474 citations

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.

1992 • 443 citations

Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung Cancer

2001 • 236 citations

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer

1998 • 176 citations

Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy

1987 • 155 citations

Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.

1996 • 132 citations

Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy.

1988 • 131 citations

Activity of docetaxel (Taxotere) in small cell lung cancer

1994 • 130 citations

Epidermal growth factor receptor expression in human lung cancer cell lines

1989 • 120 citations

Paclitaxel and Carboplatin in the Treatment of Small-Cell Lung Cancer Patients Resistant to Cyclophosphamide, Doxorubicin, and Etoposide: A Non–Cross-Resistant Schedule

1999 • 114 citations

Antitumor Activity of a Monoclonal Antibody Directed Against Gastrin-Releasing Peptide in Patients With Small Cell Lung Cancer

1997 • 112 citations

Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.

1998 • 101 citations

Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients

1993 • 75 citations

Phase II Study of Vinorelbine in Heavily Previously Treated Small Cell Lung Cancer

1996 • 74 citations

Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin.

1997 • 70 citations

Phase II Study of Paclitaxel, Ifosfamide, and Cisplatin as Second-Line Treatment in Relapsed Small-Cell Lung Cancer

2001 • 68 citations

A Phase II Study of the Immunotoxin N901-Blocked Ricin in Small-Cell Lung Cancer

2002 • 52 citations

Molecular evidence for the lack of epidermal growth factor receptor gene expression in small cell lung carcinoma cells.

1987 • 48 citations

Phase II Study of Doxorubicin and Paclitaxel as Second-Line Chemotherapy of Small-Cell Lung Cancer

2000 • 33 citations

Expression of epidermal growth factor receptors in four histologic cell types of lung cancer

1989 • 32 citations

Elimination of Neuroblastoma and Small-Cell Lung Cancer Cells With an Anti-Neural Cell Adhesion Molecule Immunotoxin

1996 • 32 citations

Pooled analysis of topotecan (T) in the second-line treatment of patients (pts) with sensitive small cell lung cancer (SCLC)

1997 • 22 citations

Combination of Cisplatin, Ifosfamide, and Irinotecan with rhG-CSF Support for the Treatment of Refractory or Relapsed Small-Cell Lung Cancer

2000 • 21 citations